Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients

NCT07338344 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Transfusion-dependent β-thalassemia Patients

Interventions

DRUG: Luspatercept combined with low-dose thalidomide
DRUG: Luspatercept plus placebo

Sponsor

Rongrong Liu